XML 42 R31.htm IDEA: XBRL DOCUMENT

Equity (Tables)

9 Months Ended

Sep. 30, 2021

Equity [Abstract]

Schedule of Equity


			Three Months Ended September 30,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at July 1, 2020			3,577			$	1,788		$	39,373		$	49,724		$	(6,393)		1,048			$	(56,850)		$	102		$	27,744
Net income attributable to Merck & Co., Inc.			—			—			—			2,941			—			—			—			—			2,941
Other comprehensive income, net of taxes			—			—			—			—			10			—			—			—			10
Cash dividends declared on common stock ($0.61 per share)			—			—			—			(1,558)			—			—			—			—			(1,558)
Share-based compensation plans and other			—			—			116			—			—			(1)			35			—			151
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			4			4
Distributions attributable to noncontrolling interests			—			—			—			—			—			—			—			(22)			(22)
Balance at September 30, 2020			3,577			$	1,788		$	39,489		$	51,107		$	(6,383)		1,047			$	(56,815)		$	84		$	29,270
Balance at July 1, 2021			3,577			$	1,788		$	44,039		$	48,777		$	(4,628)		1,044			$	(56,682)		$	94		$	33,388
Net income attributable to Merck & Co., Inc.			—			—			—			4,567			—			—			—			—			4,567
Other comprehensive income, net of taxes			—			—			—			—			38			—			—			—			38
Cash dividends declared on common stock ($0.65 per share)			—			—			—			(1,653)			—			—			—			—			(1,653)
Treasury stock shares purchased			—			—			—			—			—			8			(583)			—			(583)
Share-based compensation plans and other			—			—			110			—			—			—			21			—			131
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			4			4
Distributions attributable to noncontrolling interests			—			—			—			—			—			—			—			(29)			(29)
Balance at September 30, 2021			3,577			1,788			44,149			51,691			(4,590)			1,052			(57,244)			69			35,863


			Nine Months Ended September 30,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at January 1, 2020			3,577			$	1,788		$	39,660		$	46,602		$	(6,193)		1,038			$	(55,950)		$	94		$	26,001
Net income attributable to Merck & Co., Inc.			—			—			—			9,161			—			—			—			—			9,161
Other comprehensive loss, net of taxes			—			—			—			—			(190)			—			—			—			(190)
Cash dividends declared on common stock ($1.83 per share)			—			—			—			(4,656)			—			—			—			—			(4,656)
Treasury stock shares purchased			—			—			—			—			—			16			(1,281)			—			(1,281)
Share-based compensation plans and other			—			—			(171)			—			—			(7)			416			—			245
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			12			12
Distributions attributable to noncontrolling interests			—			—			—			—			—			—			—			(22)			(22)
Balance at September 30, 2020			3,577			1,788			39,489			51,107			(6,383)			1,047			(56,815)			84			29,270
Balance at January 1, 2021			3,577			$	1,788		$	39,588		$	47,362		$	(6,634)		1,047			$	(56,787)		$	87		$	25,404
Net income attributable to Merck & Co., Inc.			—			—			—			9,291			—			—			—			—			9,291
Other comprehensive income, net of taxes			—			—			—			—			1,595			—			—			—			1,595
Cash dividends declared on common stock ($1.95 per share)			—			—			—			(4,962)			—			—			—			—			(4,962)
Treasury stock shares purchased			—			—			—			—			—			11			(822)			—			(822)
Spin-off of Organon & Co.			—			—			4,643			—			449			—			—			(1)			5,091
Share-based compensation plans and other			—			—			(82)			—			—			(6)			365			—			283
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			12			12
Distributions attributable to noncontrolling interests			—			—			—			—			—			—			—			(29)			(29)
Balance at September 30, 2021			3,577			1,788			44,149			51,691			(4,590)			1,052			(57,244)			69			35,863